Thursday, 26 Apr 2018

You are here

Rheumatologists are Slow to Change DMARDs

The paradigm of rheumatoid arthritis (RA) therapy mandates early diagnosis and aggressive treatment.  Yet a recent cohort study has shown that RA patients with moderate to high disease activity (MHDAS) were met with infrequent DMARD adjustments; with median time to DMARD adjustment being 5 months and median time to low disease activity (LDAS) was roughly 10 months. 

Using a prospective RA cohort from the University of Pittsburg (RACER), researchers studied 538 RA patients (with 943.5 patient-years of follow-up) the found that patients in MHDAS had the following delays in DMARD adjustments:

  • 90 days: 60% of MHDAS had their DMARDs changed by 90 days
  • 154 days: Median time to adjust DMARDs in MHDAS patients
  • 301 days: Median time to achieve LDAS in MHDAS patients

Longer delays in DMARD adjustment were more likely in the elderly, lower baseline disease activity scores, longer duration of RA, and those on biologics.

Longer times to achieve LDAS was more likely in African-Americans, those with higher baseline disease activity or those not adjusting DMARD therapy within 90 days.

Such findings are not new or novel as other registries and observational cohorts have also shown therapeutic hesitancy amongst rheumatologists. Harrison et al studied 9873 RA patients in the RADIUS database. Despite having moderate activity (> 5 TJC/SJC), the percentage with no DMARD change was 67% at 6 mos., 48% at 12 mos. and 38% at 18 mos. More than half of patients (54%) did not achieve Pain VAS < 3/10 (https://buff.ly/2yx9A4d). Another prospective RA cohort study of 568 RA patients showed that 377 had severe disease and DMARD changes were variably and slowly made at 3 mos. (44%), 6 mos. (50%) or 12 mos. (68%). (https://buff.ly/2x8yt4Y)

The timeliness of DMARD adjustments in RA is a major unmet need for which many factors need to be addressed. These include the use of adjunctive therapies, treat-to-target metrics, access to care, frequency of patient evaluations and the current lack of time limits on therapeutic decision-making. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FDA Advisors Weigh COX-2 Inhibitor Safety

Should celecoxib (Celebrex) be officially declared as no riskier for the heart than other non-steroidal anti-inflammatory drugs (NSAIDs) naproxen and ibuprofen, and do those other NSAIDs interfere with aspirin for cardiovascular prevention?

Will Aspirin Cotherapy Undermine Celecoxib’s Safety Effects?

The PRECISION study took 11 years and 24,081 patients (90% OA; 10% RA). It showed that celecoxib had fewer gastrointestinal events, fewer renal events and less ATPC cardiac events compared to ibuprofen - with an 18% reduction in major CV events and a 32% reduction in all-cause mortaility compared to ibuprofen.

Medicare Drug Prices Jump Ten Times the Inflation Rate

CNN reports that a new congressional analysis of Medicare drug pricing shows the prices of the 20 most commonly prescribed brand-name drugs have risen nearly 10 times the annual rate of inflation in the past five years.

Shoe Inserts Disappoint with Plantar Heel Pain

A report from the British Journal of Sports Medicine shows that commonly used drug store shoe inserts or customized orthotics are often ineffective in managing plantar heel pain.

Leflunomide May Sensitize the Insulin Receptor and Have an Anti-Glycemic Effect

An animal model study in the Journal of Endocrinololgy reports the potential use of leflunomide in the control of hyperglycemia in male mice.